Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
ACTIVE_NOT_RECRUITING
Status
Conditions
- MSI-H Colorectal Cancer
- Melanoma
- Anal Carcinoma
- Mesothelioma
- Triple Negative Breast Cancer
- Lung Adenocarcinoma
- Cholangiocarcinoma
- Cervical Carcinoma
- Kidney Clear Cell Carcinoma
- Stomach Adenocarcinoma
- Esophageal Adenocarcinoma
- Uterine Adenocarcinoma
- Head and Neck Squamous Cell Carcinoma
- Sarcoma
- Lung Squamous Cell Carcinoma
- Urothelial Carcinoma
- Thyroid Carcinoma
- Hepatocellular Carcinoma
- Uveal Melanoma
- HER2-positive Breast Cancer
- Pancreatic Adenocarcinoma
- Squamous Esophageal Carcinoma
- Epithelial Ovarian Cancer
- Uterine Carcinosarcoma
- Small Cell Lung Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation
- Colorectal Adenocarcinoma
- Prostate Adenocarcinoma
- Carcinoma of Unknown Primary
- Other Histology
Interventions
- DRUG: Spartalizumab
- DRUG: Tislelizumab
Sponsor
SOLTI Breast Cancer Research Group
Collaborators